COMPASS Pathways Q2 2026: Cash Runway Extended into 2028, but Non-Cash Warrant Charge Drives $162.6M Net Loss
CMPS has more than doubled off its 52-week low of $3.97.
Summary
COMPASS Pathways' Q2 2026 10-Q shows $433.3 million in cash, funding operations into 2028, while a non-cash warrant liability charge drove a $162.6 million net loss. R&D spending is declining as Phase 3 trials wrap up, and G&A is rising for commercial launch preparation.
Key Events · Earnings and Guidance · CMPS
-
Cash Runway Extended into 2028
Cash and cash equivalents totaled $433.3 million as of June 30, 2026, up from $149.6 million at year-end 2025, driven by $370 million in financing activities including the February 2026 offering and warrant exercises. Management expects this to fund operations into 2028.
-
Non-Cash Warrant Charge Drives Net Loss
Net loss of $162.6 million for the six months included a $74.7 million non-cash fair value loss on warrant liabilities, reflecting the increase in share price. This is a mark-to-market accounting entry, not a cash outflow or new dilution.
-
R&D Spending Declines as Phase 3 Nears Completion
Research and development expenses fell to $55.7 million for the six months (from $61.2 million in H1 2025), primarily due to lower clinical trial costs as the Phase 3 program for COMP360 in TRD progresses toward completion.
-
G&A Rises for Commercial Preparedness
General and administrative expenses increased to $39.6 million for the six months (from $31.3 million in H1 2025), driven by higher personnel, consulting, and technology costs to support commercial launch activities.
Analysis · CMPS · Life Sciences
A robust cash position of $433.3 million extends the runway into 2028, yet a non-cash fair value loss on warrant liabilities of $74.7 million pushed the net loss to $162.6 million. As the rolling NDA submission for COMP360 in treatment-resistant depression advances, operating expenses are pivoting from R&D to commercial preparedness. The key takeaways are the cash balance and runway extension — the net loss is largely a paper loss driven by the rising share price, not operational deterioration.
At the time of this filing, CMPS was trading at $11.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $3.97 to $15.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.